Ibrutinib Improves Survival vs Chemotherapy in CNS-Involved MCL
Recommended
Ibrutinib Improves Survival vs Chemotherapy in CNS-Involved MCL
Patients with mantle cell lymphoma (MCL) and central nervous system (CNS) involvement at relapse who were treated with ibrutinib had longer overall survival (OS) than patients treated with blood-brain barrier (BBB)-crossing chemotherapy, according to results of a study published in Blood.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->